Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 plus nab-paclitaxel versus placebo plus nab-paclitaxel as first-line treatment for unresectable locally advanced or recurrent/metastatic triple-negative breast cancer
CTR20241802Phase 3Active
- Sponsor
- Biotheus
- Start
- Jun 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing PM8002 + nab-paclitaxel with Placebo + nab-paclitaxel (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Jun 2024; status: active.
02
Drugs
pumitamig
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20241802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241802.